Relevant authorities MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026) Customs and VAT EU shipments include 19% VAT
Any website or individual claiming to supply CagriSema or cagrilintide outside of a clinical trial is operating unlawfully and posing a serious risk to patient safety
Follow your healthcare provider's instructions and the product information supplied with your medication
Side effects are typically mild and include injection site reactions or transient water retention
"Expiration" in the research peptide context means loss of purity, bioactivity, or both
Remember, its crucial to consult with a healthcare professional to determine the right dosage for your specific needs